Olfati, N., Akhoundi, F. H. & Litvan, I. Atypical Parkinsonian disorders. Neurol. Clin. 43, 249–277 (2025).
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
Wenning, G. K. et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov. Disord. 37, 1131–1148 (2022).
Hoglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov. Disord. 32, 853–864 (2017).
Kovacs, G. G. Molecular pathology of neurodegenerative diseases: principles and practice. J. Clin. Pathol. 72, 725–735 (2019).
Litvan, I. et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome). Neurology 46, 922–930 (1996).
Litvan, I. et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18, 467–486 (2003).
Fox, S. H. et al. Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases. NPJ Parkinsons Dis. 11, 360 (2025).
Boxer, A. L. & Sperling, R. Accelerating Alzheimer’s therapeutic development: the past and future of clinical trials. Cell 186, 4757–4772 (2023).
Höglinger, G. U. & Lang, A. E. The why and how of the SynNerGe criteria of Parkinson´s disease. J. Neural Transm. 131, 1149–1154 (2024).
Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 20, 5143–5169 (2024).
Höglinger, G. U. et al. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 23, 191–204 (2024).
Simuni, T. et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178–190 (2024).
Siderowf, A. et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 22, 407–417 (2023).
Coughlin, D. G. et al. CSF α-synuclein seed amplification assays and skin immunofluorescence: clinical applications, research opportunities, and knowledge gaps. Neurology 106, e214648 (2026).
Zhao, Y. et al. Skin α-synuclein assays in diagnosing Parkinson’s disease: a systematic review and meta-analysis. J. Neurol. 272, 326 (2025).
Anastassiadis, C. et al. CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders. Neurology 103, e209818 (2024).
Orrú, C. D. et al. Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson’s disease: a longitudinal cohort study. Lancet Neurol. 24, 580–590 (2025).
Li, C. H. et al. Plasma pTau217 and neurofilament light chain as differentiative markers for progressive supranuclear palsy from Parkinson disease. Neurology 106, e214406 (2026).
Musso, G. et al. Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217. Front. Neurol. 16, 1638852 (2025).
Garcia-Cordero, I. et al. Evaluating the effect of Alzheimer’s disease-related biomarker change in corticobasal syndrome and progressive supranuclear palsy. Ann. Neurol. 96, 99–109 (2024).
Martinez-Valbuena, I., Fullam, S., O’Dowd, S., Tartaglia, M. C. & Kovacs, G. G. α-Synuclein seed amplification assay positivity beyond synucleinopathies. EBioMedicine 120, 105925 (2025).
Martinez-Valbuena, I., Tartaglia, M. C., Kovacs, G. G. & Lang, A. E. Copathology in atypical Parkinsonism—the rule rather than the exception? JAMA Neurol. 82, 1083–1084 (2025).
Martinez-Valbuena, I., Tartaglia, M. C., Fox, S. H., Lang, A. E. & Kovacs, G. G. Four-repeat tau seeding in the skin of patients with progressive supranuclear palsy. JAMA Neurol. 81, 1228–1230 (2024).
Wang, Z. et al. Seeding activity of skin misfolded tau as a biomarker for tauopathies. Mol. Neurodegener. 19, 92 (2024).
Dellarole, I. L. et al. Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies. NPJ Parkinsons Dis. 10, 116 (2024).
Olszewska, D. A. & Lang, A. E. How do I do a skin punch biopsy for research and diagnostic purposes in Parkinson’s disease and atypical parkinsonism? Mov. Disord. Clin. Pract. 12, 2032–2033 (2025).
Levine, T. D. & Saperstein, D. S. Routine use of punch biopsy to diagnose small fiber neuropathy in fibromyalgia patients. Clin. Rheumatol. 34, 413–417 (2015).
Edwards, C., Leira, E. C. & Gonzalez-Alegre, P. Residency training: a failed lumbar puncture is more about obesity than lack of ability. Neurology 84, e69–e72 (2015).
Coppens, S., Lehmann, S., Hopley, C. & Hirtz, C. Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges. Int. J. Mol. Sci. 24, 11624 (2023).
Sako, W., Murakami, N., Izumi, Y. & Kaji, R. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson’s disease from atypical parkinsonism: evidence from a meta-analysis. J. Neurol. Sci. 352, 84–87 (2015).
Martinez-Valbuena, I. et al. Combining skin α-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson’s disease. Mov. Disord. 37, 648–650 (2022).
Rojas, J. C. et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology 90, e273–e281 (2018).
Pedersen, C. C. et al. Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s disease. NPJ Parkinsons Dis. 10, 162 (2024).
Sanchez, E. et al. Association of plasma biomarkers with longitudinal atrophy and microvascular burden on MRI across neurodegenerative and cerebrovascular diseases. Neurology 104, e213438 (2025).
Popli, T. et al. High rates of diagnostic discordance and co-pathology: insights into PSP from the NACC dataset. Alzheimers Dement. 21, e70248 (2025).
Martinez-Valbuena, I. et al. 4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy. Nat. Commun. 17, 1006 (2025).
Driver-Dunckley, E. D. et al. Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 82, 438–451 (2023).
Kovacs, G. G. et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 126, 365–384 (2013).
Saijo, E. et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 139, 63–77 (2020).
Messerschmidt, K. et al. 18F-PI-2620 tau PET improves the imaging diagnosis of progressive supranuclear palsy. J. Nucl. Med. 63, 1754–1760 (2022).
Bernhardt, A. M. et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease. Acta Neuropathol. 149, 20 (2025).
Gerasimenko, M. et al. Biochemical signatures of skin α-synuclein in synucleinopathies revealed by RT-QuIC assay end-product analysis. Acta Neuropathol. 151, 3 (2026).
Ma, Y. et al. Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol. 23, 1225–1237 (2024).
Vaillancourt, D. E. et al. Automated imaging differentiation for parkinsonism. JAMA Neurol. 82, 495–505 (2025).
Hällqvist, J. et al. Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onset. Nat. Commun. 15, 4759 (2024).
Kovacs, G. G. et al. Biomarker-based approach to α-synucleinopathies: lessons from neuropathology. Mov. Disord. 39, 2173–2179 (2024).
Wahlund, L. O. et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32, 1318–1322 (2001).
